A prospective combination of phase II and phase III in drug development

Metron

Volumn 68, Issue 3, 2010, Pages 347-369

  Azzalini, Adelchi ^a,b   Bacchieri, Antonella ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Sigma Tau SpA   (Italy)

Author keywords

Adaptive designs; Conditional power; Drug development; Likelihoodbased inference; Skew normal distribution

Indexed keywords

EID: 79956108842     PISSN: 00261424     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03263544     Document Type: Article

References (17)

1. ARELLANO-VALLE, R. B. and AZZALINI, A. (2006) On the unification of families of skew-normal distributions, Scandinavian Journal of Statistics, 33,561-574.
2. ARELLANO-VALLE, R. B. DEL PINO, G. and SAN MARTÍN, E. (2002) Definition and probabilistic properties of skew-distribution, Statistics & Probability Letters, 58,111-121.
3. BAUER, P. and KIESER, M. (1999) Combining different phases in the development of medical treatments within a single trial, Statistics in Medicine, 18,1833-1848.
4. BAUER, P. and KOHNE, K. (1994) Evaluation of experiments with adaptive interim analyses, Biometrics, 50,1029-1041.
5. BAUER, P. and RÖHMEL, J. (1995) An adaptive method for establishing a dose-response relationship, Statistics in Medicine, 14,1595-1607.
6. CAPITANIO, A., AZZALINI, A. and STANQHELLINI, E. (2003) Graphical models for skew-normal variâtes, Scandinavian Journal of Statistics, 30,129-144.
7. Cox, D. R. and KINKLEY, D. (1974) Theoretical Statistics, Chapman and Hall, London.
8. GOULD, A. L. (2001) Sample size re-estimation: recent development and practical considerations, Statistics in Medicine, 20,2625-2643.
9. JENNISON, C. and TUMBULL, B. W. (2003) Mid-course sample size modification in clinical trials based on the observed treatment effect, Statistics in Medicine, 22,971-993.
10. Liu, Q. and PLEDGER, G. W. (2005) Phase 2 and 3 combination designs to accelerate drug development, Journal of the American Statistical Association, 100,493-502.
11. O'BRIEN, P. (1984) Procedure for comparing samples with multiple end-points, Biometrics, 40,10791087.
12. R DEVELOPMENT CORE TEAM (2006) R: A language and environment for statistical computing, R Foundation for Statistical Computing, Vienne, Austria, 3-900051-07-0.
13. RUBERO, S. J. (1995) Dose response studies. II, analysis and interpretation, J. Biopharmaceutkal Statistics, 5,15-45.
14. Corn 6 (1996), 375
15. SHUN, Z., LAN, G. and Soo, Y. (2007) Interim treatment selection using the normal approximation approach in clinical trials, Statistics in Medicine, 27,597-618.
16. STALLARD, N. and TODD, S. (2003) Sequential designs for phase III clinical trials incorporating treatment selection, Statistics in Medicine, 22,689-703.
17. TODD, S. and STALLARD, N. (2005) A new clinical trial combining phase 2 and 3: sequential designs with treatment selection and a change of endpoint, Drug Information Journal, 39,109-118.